Skip to main content
. 2023 Mar 13;199(1):13–23. doi: 10.1007/s10549-023-06895-2

Fig. 2.

Fig. 2

Cell viability assay in breast cancer cell lines. MEN1611 showed an improved in vitro antiproliferative potential in p110β-driven cellular models (PTEN loss breast cancer cells) compared to alpelisib and taselisib, while the antiproliferative activity in PIK3CA H1047R and K111N mutated breast cancer cell lines was similar among all drugs